% | $
Quotes you view appear here for quick access.

ЕЛН Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks for the post.

      BIOGEN made a clarification that the Boston Globe said "Four patients are dead", and they refuted BG and said "Patient is Alive". I'm seeing a lawsuit here for misinformation.


      The U.S. Food and Drug Administration confirmed it was evaluating a possible fourth case of the rare brain infection PML in a patient who had taken Tysabri.

      "There is a case with possible symptoms", said FDA spokeswoman Lenore Gelb, adding, "The case is being reviewed."

      The Boston Globe reported earlier that Biogen, with which Elan developed the treatment, had told the FDA a fourth patient may have contracted progressive multifocal leukoencepalopathy (PML).

      "The patient referenced in that story is alive," said Biogen spokeswoman Amy Brockelman.

      She would not confirm whether the fourth patient was suspected to have PML but said, "We are reviewing any and all suspected cases. It's an extensive evaluation. We hope to have findings by the end of the summer."

      Brockelman noted that the Boston Globe headline mentioned four patient deaths tied to Tysabri. She said two patients are confirmed to have died from PML. A third patient with a confirmed case of PML remains alive.

      PML is a rare disease in which a virus attacks the protective sheath over cells in the central nervous system.

18.12+0.2000(+1.12%)Dec 18 3:59 PMEST